



SRL 6109  
PATENT

1623  
#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Application of Richard A. Mueller et al.

Serial No. 09/249,220

Filed February 12, 1999

For USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL  
COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS

AUG 16 2000

ENTER 1600/2900

August 11, 2000

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS,

SIR:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit copies of the references listed on the attached PTO Form 1449 (modified) for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record herein.

It is believed that this Supplemental Information Disclosure Statement is being submitted prior to the issuance of a first Office action. However, if there are any fees associated with this filing, the Commissioner is hereby authorized to charge the fee to Deposit Account No. 19-1345.

Respectfully submitted,

John K. Roedel, Jr., Reg. No. 25,914  
SENNIGER, POWERS, LEAVITT & ROEDEL  
One Metropolitan Square, 16th Floor  
St. Louis, Missouri 63102  
(314) 231-5400



SRL 6109  
PATENT

RECEIVED

AUG 16 2000

TECH CENTER 160Q/2900

CERTIFICATE OF MAILING

I certify that this Information Disclosure Statement and attached PTO Form 1449 are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this 11<sup>th</sup> day of August, 2000.

*Cindy A. Ard*

Cindy A. Ard

JKRcaa  
\*Attachments